Left ventricular hypertrophy: the next treatable, silent killer?

Editorial

Julius M Gardin et al. JAMA. 2004.

. 2004 Nov 17;292(19):2396-8.

doi: 10.1001/jama.292.19.2396.

No abstract available

Comment on

Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events.
Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Wedel H, Lindholm LH, Dahlöf B; LIFE Study Investigators. Okin PM, et al. JAMA. 2004 Nov 17;292(19):2343-9. doi: 10.1001/jama.292.19.2343. JAMA. 2004. PMID: 15547161 Clinical Trial.
Prognostic significance of left ventricular mass change during treatment of hypertension.
Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V, Rokkedal J, Harris K, Aurup P, Dahlöf B. Devereux RB, et al. JAMA. 2004 Nov 17;292(19):2350-6. doi: 10.1001/jama.292.19.2350. JAMA. 2004. PMID: 15547162 Clinical Trial.